Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.28 Insider Own0.40% Shs Outstand53.00M Perf Week25.76%
Market Cap2.00B Forward P/E- EPS next Y-2.17 Insider Trans-45.60% Shs Float50.96M Perf Month18.89%
Income-243.50M PEG- EPS next Q-1.30 Inst Own81.10% Short Float18.00% Perf Quarter-30.19%
Sales1.30M P/S1542.30 EPS this Y-53.40% Inst Trans4.73% Short Ratio3.55 Perf Half Y81.35%
Book/sh8.47 P/B4.47 EPS next Y57.90% ROA-82.60% Target Price62.94 Perf Year19.60%
Cash/sh7.45 P/C5.07 EPS next 5Y-0.20% ROE-113.30% 52W Range8.00 - 63.73 Perf YTD37.91%
Dividend- P/FCF- EPS past 5Y- ROI-103.00% 52W High-40.64% Beta1.85
Dividend %- Quick Ratio6.70 Sales past 5Y-46.80% Gross Margin- 52W Low372.88% ATR2.41
Employees270 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)64.59 Volatility13.77% 7.60%
OptionableYes Debt/Eq0.05 EPS Q/Q5.90% Profit Margin- Rel Volume1.02 Prev Close36.73
ShortableYes LT Debt/Eq0.02 EarningsJan 26 BMO Payout- Avg Volume2.58M Price37.83
Recom1.90 SMA2024.17% SMA5010.61% SMA20027.70% Volume2,626,403 Change2.99%
Jan-04-17Reiterated Morgan Stanley Equal-Weight $53 → $33
Dec-22-16Initiated JP Morgan Overweight $40
Dec-20-16Initiated Goldman Neutral
Dec-16-16Reiterated RBC Capital Mkts Outperform $106 → $98
Dec-14-16Reiterated Jefferies Hold $46 → $32
Oct-28-16Reiterated RBC Capital Mkts Outperform $108 → $106
Oct-27-16Initiated Morgan Stanley Equal-Weight $53
Oct-18-16Initiated Credit Suisse Outperform $68
Oct-10-16Reiterated Wedbush Outperform $66 → $72
Sep-28-16Reiterated RBC Capital Mkts Outperform $83 → $108
Sep-20-16Reiterated Needham Buy $47 → $81
Sep-19-16Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $83
Sep-19-16Upgrade Jefferies Underperform → Hold
Sep-19-16Reiterated Robert W. Baird Outperform $23 → $102
Jul-22-16Reiterated Needham Buy $20 → $26
Jun-09-16Upgrade Piper Jaffray Underweight → Neutral
Jun-07-16Upgrade Wedbush Neutral → Outperform $36
Jun-01-16Reiterated Wedbush Outperform $14 → $23
May-03-16Downgrade Leerink Partners Mkt Perform → Underperform
Apr-29-16Downgrade Jefferies Hold → Underperform
Jan-13-17 07:23PM  Cramer lists the stocks that you should take the cash and run on at CNBC
04:36PM  Surge From Bank Earnings Doesn't Last
Jan-12-17 10:12AM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : January 12, 2017
Jan-11-17 02:17PM  Sarepta Therapeutics Inc (SRPT) Gets Off To A Running Start With Eteplirsen at Insider Monkey -6.18%
12:25PM  Is This Going To Be Sarepta Therapeutics' Year? at Motley Fool
10:38AM  Sarepta Therapeutics: Reports of Its Demise Appear 'Greatly Exaggerated' at
09:46AM  Sarepta Muscular Dystrophy Drug Posts Solid Sales at Investopedia
09:30AM  Latest Reports on Sarepta Therapeutics and Cempra as the NASDAQ Continues to Hit Record Highs Accesswire
09:20AM  7 Stocks Making Big Moves With Unusual Volume
08:35AM  Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?
07:28AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : January 11, 2017
Jan-10-17 05:09PM  What Sarepta Therapeutics' CEO Said That Made the Stock Soar at Motley Fool +21.21%
03:30PM  Tuesdays Top Biopharma Movers
12:55PM  Sarepta gains $300M in value as Duchenne drug launch beats expectations at
12:49PM  For Sarepta, Today's Good News Might Be Just The Beginning
11:54AM  Why Sarepta Therapeutics Has Soared 20% at
11:38AM  Sarepta Soars Following Encouraging Exondys 51 News
11:22AM  Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears at TheStreet
10:33AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur
10:33AM  Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears
10:20AM  Sarepta eyes a different approach to Duchenne: gene therapy at
08:38AM  3 Tempting Stocks We're Avoiding at Motley Fool
08:30AM  Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Childrens Hospital for Microdystrophin Gene Therapy Program Business Wire
08:30AM  Sarepta Therapeutics Enters into License Agreement with Nationwide Childrens Hospital for Galgt2 Gene Therapy Program Business Wire
Jan-09-17 09:15AM  Biotech Industry Off to a Strong Start in 2017 Latest Reports on Sarepta Therapeutics and Momenta Pharmaceuticals Accesswire
Jan-06-17 07:20AM  Cambridge's Akashi plans clinical tests of three Duchenne drugs this year at
Jan-05-17 02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at
11:25AM  Sarepta Therapeutics: How Shares Could Double Despite the Hurdles at
07:21AM  Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified
06:21AM  What Biotech Investors Can Expect from the J.P. Morgan Healthcare Conference 2017
Jan-04-17 11:39AM  Sarepta Therapeutics: Slow Going? at
10:56AM  Trying to Knock Out Some Individual Trades, but it Is not Easy
Jan-03-17 08:30AM  Sarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-02-17 11:46PM  [$$] The FDAs Rigged Drug Committees at The Wall Street Journal
Dec-30-16 07:15PM  [$$] The FDA's Rigged Drug Committees at The Wall Street Journal
05:05PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
12:58PM  Why health insurers wont cover this $300,000-a-year rare disease drug at MarketWatch
11:15AM  3 Sleeper Biotechs That Could Bounce Back Strong in 2017
Dec-27-16 02:32PM  Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
Dec-23-16 11:42AM  Shark Bites: We Knew Today Would Be Slow, but Come On +6.18%
11:41AM  Sarepta Therapeutics: 'Rare Diseases Launches, Always Complex' at
Dec-22-16 05:52PM  Biotech buying opportunity?
12:47PM  2 Opposing Views On The Future Of Sarepta
11:20AM  What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
10:27AM  Sarepta Therapeutics: Poised for a Rebound? at
09:24AM  2016 Was a Terrible Year for Biotech but the Tweets Were on Point
06:19AM  Coverage initiated on Sarepta Therapeutics by JP Morgan
Dec-21-16 10:36AM  Sarepta Therapeutics: An Appropriate Selloff? at
Dec-20-16 05:45PM  Sarepta's (SRPT) Application for DMD Drug Accepted in the EU
01:06PM  For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
10:01AM  Sarepta Therapeutics: Watch and Wait, Goldman Sachs Says at
Dec-19-16 05:23PM  Sarepta Therapeutics Announces EMA Validation of Eteplirsen Authorization Application for Treatment of Duchenne Muscular Dystrophy Amenable to Exon Skipping 51 Business Wire
09:10AM  The Best Biopharma CEOs of 2016 Are...
Dec-15-16 11:03AM  Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups
Dec-14-16 04:17PM  Anthem, Humana, United Push Back On Sarepta's FDA-Approved DMD Drug -5.78%
02:13PM  Will Insurers Pay For Sarepta's DMD Drug? at
12:51PM  FDA's Woodcock speaks out about one of the agency's most controversial decisions at CNBC
07:30AM  [$$] Gormley's Take: Biotech Startups Heed Tough Lessons from a Drugmaker's Controversy at The Wall Street Journal
Dec-09-16 03:02PM  Should You Be Concerned That Smart Money Is Fleeing ALLETE Inc (ALE)? at Insider Monkey -5.31%
Dec-07-16 06:49PM  PTC Therapeutics, Inc. in 3 Charts at Motley Fool
02:46PM  Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally
04:03AM  Hedge Funds Are Crazy About Sarepta Therapeutics Inc (SRPT) at Insider Monkey
Dec-05-16 09:23AM  Is This Why Sarepta Therapeutics Fell 14.5% in November? at Motley Fool
Dec-02-16 03:24PM  Sarepta Drug Gets UnitedHealth Coverage (SRPT, UNH) at Investopedia
11:33AM  New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51
Dec-01-16 11:47AM  5 Medical Tech Stocks You Should Be Investing In at Insider Monkey -6.01%
11:05AM  Sarepta: UnitedHealth Induced Selloff a Buying Opportunity? at
Nov-30-16 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -6.70%
04:10PM  The 21st Century Cures Act Will Not Fix The FDA at Forbes
Nov-29-16 01:55PM  Sarepta Therapeutics: A Mistake to Underestimate Its Sales, Baird Says at
Nov-21-16 02:19PM  Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
Nov-17-16 01:04PM  SAREPTA THERAPEUTICS, INC. Financials
09:28AM  10 biotech companies ripe for a buyout, courtesy of Donald Trump at MarketWatch
08:56AM  3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise
Nov-14-16 12:10PM  Why PTC Therapeutics Is Soaring Again at Motley Fool
07:58AM  How Donald Trump May Impact The FDA at Forbes
Nov-11-16 01:25PM  Why not everyone is buying the market hype surrounding Sareptas Duchenne drug at
10:30AM  3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'
08:10AM  PTC Therapeutics Duchenne Drug Wins Extended European Approval
01:00AM  Trump presidency could prove a salve for pharma merger deals Reuters
Nov-08-16 05:40PM  Why Cempra Inc Fell Over the Last 2 Days at Motley Fool
12:53PM  Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors Q3 Returns; See How Other Investments Performed at Insider Monkey
Nov-07-16 08:33AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-04-16 08:30AM  Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare Conference Business Wire +5.52%
Nov-01-16 01:13PM  4 Stocks I'd Avoid at All Costs at Motley Fool
Oct-31-16 05:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-29-16 08:16AM  3 Stocks to Avoid in Biotech at Motley Fool
Oct-28-16 12:56PM  Sarepta Therapeutics Inc. (SRPT) Stock: Jason Karp Is A Shareholder Again And Has A Larger Position Than Ever at Insider Monkey
10:04AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : October 28, 2016
09:35AM  Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3
Oct-27-16 02:32PM  Why Sarepta is Sinking at -8.37%
01:24PM  Edited Transcript of SRPT earnings conference call or presentation 27-Oct-16 12:00pm GMT
08:41AM  Sarepta Therapeutics reports 3Q loss
08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:28AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q3 2016 Sarepta Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments Business Wire
Oct-25-16 01:34PM  Sarepta: 'Setting Aside the Controversy Around the Questionable Data' at
Oct-24-16 08:30AM  Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016 Business Wire
Oct-21-16 08:00AM  Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company's lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDPresident, CEO & CMONov 09Option Exercise8.283,00024,84075,635Nov 10 08:19 AM
Howton David TSVP, General CounselNov 09Option Exercise23.851,00023,85022,453Nov 10 08:27 AM
Mahatme SandeshSenior Vice President, CFONov 09Option Exercise23.851,00023,85032,532Nov 10 08:26 AM
Ruff ShamimSVP, Regulatory Affairs & QualNov 08Option Exercise26.241,00026,24021,239Nov 10 08:20 AM
Mahatme SandeshSenior Vice President, CFOOct 17Option Exercise13.9030,000417,00061,532Oct 19 04:22 PM
Mahatme SandeshSenior Vice President, CFOOct 17Sale50.0830,0001,502,50231,532Oct 19 04:22 PM
Howton David TSVP, General CounselSep 22Option Exercise13.907,00097,30028,453Sep 26 04:19 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Option Exercise8.2840,179332,682117,162Sep 26 04:23 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Option Exercise13.907,311101,62327,550Sep 30 09:58 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Sale60.007,311438,66020,239Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Sale60.0040,1792,410,74076,983Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Sale60.007,000420,00021,453Sep 26 04:19 PM
Howton David TSVP, General CounselSep 19Option Exercise13.908,000111,20011,168Sep 21 09:28 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Option Exercise6.9424,352168,94189,983Sep 21 09:29 PM
Aphale JayantVP, Technical OperationsSep 19Option Exercise4.6235,000161,70036,490Sep 21 09:31 PM
Aphale JayantVP, Technical OperationsSep 19Sale50.0035,0001,750,00011,490Sep 21 09:31 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Sale50.0024,3521,217,60076,983Sep 21 09:29 PM
Howton David TSVP, General CounselSep 19Sale50.009,304465,2003,168Sep 21 09:28 PM
Kaye Edward M. MDSVP Interim CEO & CMOSep 14Sale30.0024,557736,71076,983Sep 16 04:04 PM
BEHRENS M KATHLEENDirectorMar 16Buy14.5410,000145,43321,855Mar 16 08:15 PM
BEHRENS M KATHLEENDirectorMar 14Buy16.5465,0001,075,276112,166Mar 16 08:15 PM
Barry RichardDirectorMar 14Buy15.6675,0001,174,1853,241,014Mar 16 08:09 PM